Nicholas M Smith1,2, Zackery P Bulman1,2, Arthur O Sieron3, Jürgen B Bulitta4, Patricia N Holden1,2, Roger L Nation5, Jian Li5, Gerard D Wright3, Brian T Tsuji1,2. 1. Laboratory for Antimicrobial Pharmacodynamics, University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA. 2. New York State Center of Excellence in Life Sciences and Bioinformatics, Buffalo, NY, USA. 3. Michael G. DeGroote Institute for Infectious Disease Research and the Department of Biochemistry and Biomedical Sciences, McMaster University, Ontario, Canada. 4. Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA. 5. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.
Abstract
Objectives: Gram-negative bacteria harbouring the mcr-1 plasmid are resistant to the 'last-line' polymyxins and have been reported worldwide. Our objective was to define the impact of increasing the initial polymyxin B dose intensity against an mcr-1 -harbouring strain to delineate the impact of plasmid-mediated polymyxin resistance on the dynamics of bacterial killing and resistance. Methods: A hollow fibre infection model (HFIM) was used to simulate polymyxin B regimens against an mcr-1 -harbouring Escherichia coli (MIC 8 mg/L) over 10 days. Four escalating polymyxin B 'front-loading' regimens (3.33, 6.66, 13.3 or 26.6 mg/kg for one dose followed by 1.43 mg/kg every 12 h starting 12 h later) simulating human pharmacokinetics were utilized in the HFIM. A mechanism-based, mathematical model was developed using S-ADAPT to characterize bacterial killing. Results: The 3.33 mg/kg 'front-loading' regimen resulted in regrowth mirroring the growth control. The 6.66, 13.3 and 26.6 mg/kg 'front-loading' regimens resulted in maximal bacterial reductions of 1.91, 3.79 and 6.14 log 10 cfu/mL, respectively. Irrespective of the early polymyxin B exposure (24 h AUC), population analysis profiles showed similar growth of polymyxin B-resistant subpopulations. The HFIM data were well described by the mechanism-based model integrating three subpopulations (susceptible, intermediate and resistant). Compared with the susceptible subpopulation of mcr-1 -harbouring E. coli , the resistant subpopulation had an approximately 10-fold lower rate of killing due to polymyxin B treatment. Conclusions: Manipulating initial dose intensity of polymyxin B was not able to overcome plasmid-mediated resistance due to mcr-1 in E. coli . This reinforces the need to develop new combinatorial strategies to combat these highly resistant Gram-negative bacteria.
Objectives: Gram-negative bacteria harbouring the mcr-1 plasmid are resistant to the 'last-line' polymyxins and have been reported worldwide. Our objective was to define the impact of increasing the initial polymyxin B dose intensity against an mcr-1 -harbouring strain to delineate the impact of plasmid-mediated polymyxin resistance on the dynamics of bacterial killing and resistance. Methods: A hollow fibre infection model (HFIM) was used to simulate polymyxin B regimens against an mcr-1 -harbouring Escherichia coli (MIC 8 mg/L) over 10 days. Four escalating polymyxin B 'front-loading' regimens (3.33, 6.66, 13.3 or 26.6 mg/kg for one dose followed by 1.43 mg/kg every 12 h starting 12 h later) simulating human pharmacokinetics were utilized in the HFIM. A mechanism-based, mathematical model was developed using S-ADAPT to characterize bacterial killing. Results: The 3.33 mg/kg 'front-loading' regimen resulted in regrowth mirroring the growth control. The 6.66, 13.3 and 26.6 mg/kg 'front-loading' regimens resulted in maximal bacterial reductions of 1.91, 3.79 and 6.14 log 10 cfu/mL, respectively. Irrespective of the early polymyxin B exposure (24 h AUC), population analysis profiles showed similar growth of polymyxin B-resistant subpopulations. The HFIM data were well described by the mechanism-based model integrating three subpopulations (susceptible, intermediate and resistant). Compared with the susceptible subpopulation of mcr-1 -harbouring E. coli , the resistant subpopulation had an approximately 10-fold lower rate of killing due to polymyxin B treatment. Conclusions: Manipulating initial dose intensity of polymyxin B was not able to overcome plasmid-mediated resistance due to mcr-1 in E. coli . This reinforces the need to develop new combinatorial strategies to combat these highly resistant Gram-negative bacteria.
Authors: Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji Journal: J Antimicrob Chemother Date: 2016-09-15 Impact factor: 5.790
Authors: Michael R Mulvey; Laura F Mataseje; James Robertson; John H E Nash; Patrick Boerlin; Baldwin Toye; Rebecca Irwin; Roberto G Melano Journal: Lancet Infect Dis Date: 2016-03 Impact factor: 25.071
Authors: Jennifer Coetzee; Craig Corcoran; Elizabeth Prentice; Mischka Moodley; Marc Mendelson; Laurent Poirel; Patrice Nordmann; Adrian John Brink Journal: S Afr Med J Date: 2016-04-19
Authors: Michel Doumith; Gauri Godbole; Philip Ashton; Lesley Larkin; Tim Dallman; Martin Day; Michaela Day; Berit Muller-Pebody; Matthew J Ellington; Elizabeth de Pinna; Alan P Johnson; Katie L Hopkins; Neil Woodford Journal: J Antimicrob Chemother Date: 2016-04-18 Impact factor: 5.790
Authors: Gauri G Rao; Neang S Ly; Curtis E Haas; Samira Garonzik; Alan Forrest; Jurgen B Bulitta; Pamela A Kelchlin; Patricia N Holden; Roger L Nation; Jian Li; Brian T Tsuji Journal: Antimicrob Agents Chemother Date: 2013-12-16 Impact factor: 5.191
Authors: Peter J Collignon; John M Conly; Antoine Andremont; Scott A McEwen; Awa Aidara-Kane; Yvonne Agerso; Antoine Andremont; Peter Collignon; John Conly; Tran Dang Ninh; Pilar Donado-Godoy; Paula Fedorka-Cray; Heriberto Fernandez; Marcelo Galas; Rebecca Irwin; Beth Karp; Gassan Matar; Patrick McDermott; Scott McEwen; Eric Mitema; Richard Reid-Smith; H Morgan Scott; Ruby Singh; Caroline Smith DeWaal; John Stelling; Mark Toleman; Haruo Watanabe; Gun-Jo Woo Journal: Clin Infect Dis Date: 2016-07-20 Impact factor: 9.079
Authors: Phillip J Bergen; Zackery P Bulman; Cornelia B Landersdorfer; Nicholas Smith; Justin R Lenhard; Jürgen B Bulitta; Roger L Nation; Jian Li; Brian T Tsuji Journal: Infect Dis Ther Date: 2015-12-08
Authors: Soon-Ee Cheah; Matthew D Johnson; Yan Zhu; Brian T Tsuji; Alan Forrest; Jurgen B Bulitta; John D Boyce; Roger L Nation; Jian Li Journal: Sci Rep Date: 2016-05-19 Impact factor: 4.379
Authors: N J Onufrak; N M Smith; M J Satlin; J B Bulitta; X Tan; P N Holden; R L Nation; J Li; A Forrest; B T Tsuji; Z P Bulman Journal: Clin Microbiol Infect Date: 2020-05-05 Impact factor: 8.067
Authors: Nicholas M Smith; Katie Rose Boissonneault; Liang Chen; Vidmantas Petraitis; Ruta Petraitiene; Xun Tao; Jieqiang Zhou; Yinzhi Lang; Povilas Kavaliauskas; Zackery P Bulman; Patricia N Holden; Raymond Cha; Jürgen B Bulitta; Barry N Kreiswirth; Thomas J Walsh; Brian T Tsuji Journal: Antimicrob Agents Chemother Date: 2022-08-04 Impact factor: 5.938
Authors: N M Smith; J R Lenhard; K R Boissonneault; C B Landersdorfer; J B Bulitta; P N Holden; A Forrest; R L Nation; J Li; B T Tsuji Journal: Clin Microbiol Infect Date: 2020-02-12 Impact factor: 8.067
Authors: Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye Journal: Pharmacotherapy Date: 2019-01 Impact factor: 6.251
Authors: Zackery P Bulman; Liang Chen; Thomas J Walsh; Michael J Satlin; Yuli Qian; Jürgen B Bulitta; Charles A Peloquin; Patricia N Holden; Roger L Nation; Jian Li; Barry N Kreiswirth; Brian T Tsuji Journal: MBio Date: 2017-07-25 Impact factor: 7.867
Authors: Michael Maynard; G L Drusano; Michael Vicchiarelli; Weiguo Liu; Jenny Myrick; Jocelyn Nole; Brandon Duncanson; David Brown; Arnold Louie Journal: Antimicrob Agents Chemother Date: 2021-07-16 Impact factor: 5.191